Premium
Rat pancreas after long‐term treatment with the somatostatin analogue octreotide
Author(s) -
von Schonfeld J,
Meisse F,
Muller MK
Publication year - 1995
Publication title -
experimental physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.925
H-Index - 101
eISSN - 1469-445X
pISSN - 0958-0670
DOI - 10.1113/expphysiol.1995.sp003900
Subject(s) - somatostatin , medicine , endocrinology , pancreas , octreotide , cholecystokinin , amylase , glucagon , endocrine system , chemistry , trypsin , biology , insulin , hormone , enzyme , biochemistry , receptor
Somatostatin is a potent inhibitor of endocrine and exocrine pancreatic secretion. However, it is not clear whether it also inhibits pancreatic growth. Therefore we treated male Wistar rats with a somatostatin analogue, octreotide (12‐192 micrograms/(kg body wt.day)), over a period of 14 days. In a dose‐dependent manner, this potent and long‐acting analogue caused a reduction in weight of the pancreas and a reduction in pancreatic content of protein, DNA, trypsin, chymotrypsin, amylase and lipase, as well as pancreatic content of insulin‐, glucagon‐ and somatostatin‐like immunoreactivities. When growth of rat pancreas was induced by oral administration of camostate (200 mg/(kg body wt. day) or by subcutaneous administration of cholecystokinin (2 x 10 micrograms/(kg body wt. day)) over a period of 14 days, octreotide (12‐192 micrograms/(kg body wt.day)) had the same effects, but these were even more pronounced. We conclude that somatostatin is an important regulator of pancreatic growth.